A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease
NCT ID: NCT07252440
Last Updated: 2025-11-26
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2
Total Enrollment
180 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-12-05
Study Completion Date
2028-11-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a multicenter, randomized, double-blind, placebo-controlled parallel Phase II core period study to evaluate the efficacy and safety of TTYP01 Tablets in early symptomatic AD (Mild cognitive impairment \[MCI\] due to AD, or mild AD dementia).
A total of 180 participants will be randomized into 3 parallel groups: 2 TTYP01 dose groups and 1 placebo group.
A total of 180 participants will be randomized into 3 parallel groups: 2 TTYP01 dose groups and 1 placebo group.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)
NCT02079909
Alzheimer's Disease
COMPLETED
PHASE2
A Safety Study of TTP4000 in Subjects With Alzheimer's Disease
NCT01548430
Alzheimer's Disease
COMPLETED
PHASE1
Evaluate the Safety and Efficacy of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease
NCT03790982
Alzheimer's Disease
UNKNOWN
PHASE2
Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
NCT04191486
Mild Cognitive Impairment
COMPLETED
PHASE2
Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease
NCT00663936
Alzheimer's Disease
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
AD
Early Alzheimer's Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low-dose group
60 mg (2 TTYP01 30 mg tablets + 1 placebo tablet) BID
Group Type
EXPERIMENTAL
TTYP01 tables 60mg
Intervention Type
DRUG
2 TTYP01 30 mg tablets + 1 placebo tablet BID
High-dose group
90 mg (3 TTYP01 30 mg tablets) BID
Group Type
ACTIVE_COMPARATOR
TTYP01 tables 90mg
Intervention Type
DRUG
(3 TTYP01 30 mg tablets
Placebo group
3 placebo tablets, BID
Group Type
PLACEBO_COMPARATOR
TTYP01 tables 0mg
Intervention Type
DRUG
3 placebo tablets
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TTYP01 tables 60mg
2 TTYP01 30 mg tablets + 1 placebo tablet BID
Intervention Type
DRUG
TTYP01 tables 90mg
(3 TTYP01 30 mg tablets
Intervention Type
DRUG
TTYP01 tables 0mg
3 placebo tablets
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Participants must meet all the following criteria to be eligible for this study:
1. Age between 60 and 85 years (inclusive, based on the date of signing the informed consent), applicable to all genders.
2. Must meet the 2024 Alzheimer's Association (AA) Workgroup revised criteria for diagnosing MCI due to AD or mild AD dementia.
3. CDR score: At screening and baseline, the CDR global score must be 0.5 or 1.0, and the CDR memory score must be 0.5 or higher.
4. MMSE score: At screening, the MMSE score must be 22 or higher.
5. Body mass index (BMI): At screening, BMI must be greater than 17 and less than 35 (inclusive).
6. History of memory decline: A history of at least 6 months of gradual and progressive memory decline prior to signing ICF must be reported and confirmed by an informant.
7. Blood p-tau 217: positive (For participants with evidence suggesting Aβ-PET positivity, absence blood p-tau 217 determination is not considered a protocol deviation.).
8. Aβ- PET scan: Visual read of Aβ-PET scan must be positive.
9. Study partner: Must have a designated study partner who can support the participants and spend at least 8 h per week with them during the study. The partner must provide a separate written informed consent and be willing and able to provide follow-up information about the participant. They should regularly spend enough time with the participants to reliably meet study requirements. The study partner does not need to live with the participant but should be easily reachable during the study. If the partner is unable to continue supporting due to health or other reasons, it is allowed to replace with another eligible partner. The replacement partner must provide a separate written informed consent and be willing and able to provide follow-up information about the participant.
10. Concomitant medication: Participants who are receiving cholinesterase inhibitors and/or memantine for AD can be enrolled into the study, but must be on a stable dose for at least 12 weeks prior to baseline. For all other (i.e., non-AD-related) allowed concomitant medications, participants must receive a stable dose (not for topical, as needed \[PRN\], or discontinued medications) for at least 4 weeks prior to baseline unless otherwise stated.
11. Contraception:
a.Male participants i.Male participants, regardless of childbearing potential, if their non-pregnant female partner is a female of childbearing potential, must agree to maintain abstinence (if this is their preferred and usual lifestyle) or to use a barrier method and another highly effective (failure rate less than 1%) method of contraception (see Section 17.5 for details) until 90 days after the last dose of IP.
ii.Male participants with pregnant partners should use condoms during intercourse for the duration of the study and until the end of the estimated relevant potential exposure for women of childbearing potential (WOCBP; expected to be 90 days after the last dose of IP).
iii.Male participants should refrain from sperm donation for the duration of the study and until 90 days following the last dose of IP.
b.Female participants i.WOCBP must use, or be willing to use, two forms of effective contraception (a barrier method and one other highly effective method of contraception, as detailed in Section 17.5) during participation in the trial and for 90 days after the last dose of the IP.
ii.WOCBP potential is defined as those who are:
① Following menarche
② From the time of menarche until becoming postmenopausal unless permanently sterile (see below) A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
* In the absence of 12 months of amenorrhea, confirmation with more than one follicle-stimulating hormone (FSH) measurement is required.
* Individuals receiving hormone replacement therapy (HRT) whose menopausal status is in doubt will be required to use a non-estrogenic, highly effective contraceptive method if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.
Permanent sterilization methods and gender-affirming procedures (for the purpose of this study) include:
* Documented hysterectomy
* Documented bilateral salpingectomy
* Documented bilateral oophorectomy
* For individuals with permanent infertility due to an alternate medical cause other than the above, (e.g., Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), investigator discretion should be applied to determining study entry.
iii.All WOCBP must be negative at Visit 1 based on a serum pregnancy test.
12. Informed consent: Must obtain a voluntary signed ICF, approved by an Ethics Committee, from the participants or their legal representative before any study procedure.
13. Language proficiency: Must be fluent in the language used at the study site.
14. Protocol compliance: Must be willing and able to comply with all aspects of the protocol.
1. Age between 60 and 85 years (inclusive, based on the date of signing the informed consent), applicable to all genders.
2. Must meet the 2024 Alzheimer's Association (AA) Workgroup revised criteria for diagnosing MCI due to AD or mild AD dementia.
3. CDR score: At screening and baseline, the CDR global score must be 0.5 or 1.0, and the CDR memory score must be 0.5 or higher.
4. MMSE score: At screening, the MMSE score must be 22 or higher.
5. Body mass index (BMI): At screening, BMI must be greater than 17 and less than 35 (inclusive).
6. History of memory decline: A history of at least 6 months of gradual and progressive memory decline prior to signing ICF must be reported and confirmed by an informant.
7. Blood p-tau 217: positive (For participants with evidence suggesting Aβ-PET positivity, absence blood p-tau 217 determination is not considered a protocol deviation.).
8. Aβ- PET scan: Visual read of Aβ-PET scan must be positive.
9. Study partner: Must have a designated study partner who can support the participants and spend at least 8 h per week with them during the study. The partner must provide a separate written informed consent and be willing and able to provide follow-up information about the participant. They should regularly spend enough time with the participants to reliably meet study requirements. The study partner does not need to live with the participant but should be easily reachable during the study. If the partner is unable to continue supporting due to health or other reasons, it is allowed to replace with another eligible partner. The replacement partner must provide a separate written informed consent and be willing and able to provide follow-up information about the participant.
10. Concomitant medication: Participants who are receiving cholinesterase inhibitors and/or memantine for AD can be enrolled into the study, but must be on a stable dose for at least 12 weeks prior to baseline. For all other (i.e., non-AD-related) allowed concomitant medications, participants must receive a stable dose (not for topical, as needed \[PRN\], or discontinued medications) for at least 4 weeks prior to baseline unless otherwise stated.
11. Contraception:
a.Male participants i.Male participants, regardless of childbearing potential, if their non-pregnant female partner is a female of childbearing potential, must agree to maintain abstinence (if this is their preferred and usual lifestyle) or to use a barrier method and another highly effective (failure rate less than 1%) method of contraception (see Section 17.5 for details) until 90 days after the last dose of IP.
ii.Male participants with pregnant partners should use condoms during intercourse for the duration of the study and until the end of the estimated relevant potential exposure for women of childbearing potential (WOCBP; expected to be 90 days after the last dose of IP).
iii.Male participants should refrain from sperm donation for the duration of the study and until 90 days following the last dose of IP.
b.Female participants i.WOCBP must use, or be willing to use, two forms of effective contraception (a barrier method and one other highly effective method of contraception, as detailed in Section 17.5) during participation in the trial and for 90 days after the last dose of the IP.
ii.WOCBP potential is defined as those who are:
① Following menarche
② From the time of menarche until becoming postmenopausal unless permanently sterile (see below) A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
* In the absence of 12 months of amenorrhea, confirmation with more than one follicle-stimulating hormone (FSH) measurement is required.
* Individuals receiving hormone replacement therapy (HRT) whose menopausal status is in doubt will be required to use a non-estrogenic, highly effective contraceptive method if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.
Permanent sterilization methods and gender-affirming procedures (for the purpose of this study) include:
* Documented hysterectomy
* Documented bilateral salpingectomy
* Documented bilateral oophorectomy
* For individuals with permanent infertility due to an alternate medical cause other than the above, (e.g., Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), investigator discretion should be applied to determining study entry.
iii.All WOCBP must be negative at Visit 1 based on a serum pregnancy test.
12. Informed consent: Must obtain a voluntary signed ICF, approved by an Ethics Committee, from the participants or their legal representative before any study procedure.
13. Language proficiency: Must be fluent in the language used at the study site.
14. Protocol compliance: Must be willing and able to comply with all aspects of the protocol.
Exclusion Criteria
1. History of intracranial infection or traumatic brain injury.
2. Severe coronary heart disease, cardiac insufficiency (New York Heart Association Class Ⅲ and Class IV), atrial fibrillation, and other heart diseases within six months prior to signing ICF.
3. Malignancy:
* History of cancer within the last 3 years, with the exception of non-metastatic basal and/or squamous cell carcinoma of the skin, in situ cervical cancer, nonprogressive prostate cancer, or other cancers with a low risk of recurrence or spread.
* Intracranial space occupying lesions or brain tumors will be excluded unless, based on the opinion of the investigators and medical monitors, the medical condition will not interfere with cognitive assessments and safety.
4. Severe hematologic disorders, such as myelodysplastic syndrome, aplastic anemia, lymphoma, leukemia, etc.
5. Peptic ulcer or obstruction or other diseases that affect the absorption of oral medication.
6. Any neurological disorder that may cause cognitive impairment beyond the impact of AD.
7. Any psychiatric diagnosis or neuropsychiatric symptom (such as hallucinations, major depression, or delusions) that may interfere with the participant's study procedure.
8. A history of transient ischemic attack (TIA), stroke, or seizure in the 12 months prior to signing ICF.
9. The Hachinski Ischemic Index Scale (HIS) at screening \> 4 points.
10. ECG at screening or at baseline showing prolonged QTcF \[Fridericia correction formula, see Section 17.4\] (QTcF \> 480 ms in women; QTcF \> 470 ms in men) or other clinically significant abnormalities of the ECG that are considered by the investigator to be unsuitable for participation in a clinical study (e.g., heart rate \< 50 beats/min, sinus node lesions, Morse II or third-degree atrioventricular block, etc.).
11. The Geriatric Depression Scale (GDS) score at screening ≥ 8 points.
12. Contraindications to MRI scans, including pacemakers/defibrillators, ferromagnetic metal implants (in addition to those approved for safe use in MRI scanners, such as cranial and cardiac devices).
13. Contraindications with PET scanning, allergies to tracers.
14. Brain MRI at screening reveals evidence of other clinically significant lesions, suggesting a possible diagnosis of dementia other than AD.
15. Brain MRI at screening reveals the presence of a single hemorrhage with a maximum diameter \> 10 mm and investigator assesses the participant is unsuitable for this study; Evidence of angioedema.
16. Participants with inadequately controlled bleeding disorder (including platelet count \< 100,000/µL or international normalized ratio \[INR\] \> 1.5).
17. Thyroid stimulating hormone levels above or below the normal range. Participants with results of other thyroid function tests that fall outside the normal range will be excluded only if they are considered clinically significant by the investigator.
18. Laboratory test results for serum vitamin B12 levels below the normal range, as well as participants who are receiving vitamin B12 supplement therapy.
19. Positive serological finding for human immunodeficiency virus (HIV), active syphilis, Hepatitis B surface antigen (HBsAg), or Hepatitis C virus (HCV) antibody.
20. Any other clinically significant abnormalities in physical examination, vital signs, laboratory tests, or ECG present at screening or baseline that the investigator determines the situations that affected the safety of the participants or other interferences with the study.
21. Have a known or suspected history of drug or alcohol abuse.
22. Serious or unstable disease, or any other medical condition (e.g., heart, respiratory, gastrointestinal, liver, kidney, endocrine and nervous system disease, including poorly controlled hypertension, with a systolic blood pressure of ≥160mmHg or a diastolic blood pressure of ≥100 mmHg; Poorly controlled diabetes, etc.) that the investigator believes may affect the participant's safety or interfere with study evaluation.
23. Previous use of prohibited drugs, including disease-modifying drugs (Such as approved lecanemab, donemab, etc. or other disease-modifying investigational medicinal products), anti-oxidative stress drugs (other formulations of edaravone).
24. Have scheduled surgical procedures requiring general anesthesia during the study period. For a scheduled procedure that requires only local anesthesia and performed as a day procedure without the need for post-operative hospitalization, participant does not need to be excluded if the investigator determines that the procedure does not interfere with study procedures or participant safety.
25. Severe vision, hearing, reading, comprehension, or physical dysfunction that prevents the participant from accurately performing neuropsychological tests.
26. Have been diagnosed with serious active liver disease, such as acute hepatitis, chronic active hepatitis, cirrhosis, etc., or alanine transaminase (ALT) \> 2 × upper limit of normal (ULN) or aspartate aminotransferase (AST) \> 2 × ULN, or total bilirubin (TBIL) \> 1.5 × ULN.
27. Have been diagnosed with severe active kidney disease, renal insufficiency; or serum creatinine \> 1.5 × ULN or creatinine clearance \< 50 mL/min at screening and baseline (Calculated based on the Cockcroft-Gault formula, see Section 17.6 for details).
28. Have severe systemic disease and life expectancy is \< 2 years.
29. Answer "yes" to C-SSRS suicidal ideation Type 4 or 5, or any suicidal behavior assessment within 6 months before screening, at screening, or at the baseline visit, or has been hospitalized or treated for suicidal behavior in the past 5 years before screening.
30. Allergic to edaravone, sodium bisulfite, or soluplus excipients (Note: Asthma patients are sensitive to sulfites and may have allergic reactions. For patients with a history of asthma, the investigator will carefully assess whether to enroll them.).
31. History of major surgery within 4 weeks prior to enrollment.
33. Participants who have received cholinesterase inhibitors, memantine within 12 weeks prior to randomization and stopped treatment due to safety concerns or other reasons and refuse to or unable to receive it again.
34. Female participants who are pregnant, breastfeeding, planning to become pregnant recently, or unwilling to use contraceptive measures.
35. Have other conditions that investigator believes the participant is unsuitable for this study.
2. Severe coronary heart disease, cardiac insufficiency (New York Heart Association Class Ⅲ and Class IV), atrial fibrillation, and other heart diseases within six months prior to signing ICF.
3. Malignancy:
* History of cancer within the last 3 years, with the exception of non-metastatic basal and/or squamous cell carcinoma of the skin, in situ cervical cancer, nonprogressive prostate cancer, or other cancers with a low risk of recurrence or spread.
* Intracranial space occupying lesions or brain tumors will be excluded unless, based on the opinion of the investigators and medical monitors, the medical condition will not interfere with cognitive assessments and safety.
4. Severe hematologic disorders, such as myelodysplastic syndrome, aplastic anemia, lymphoma, leukemia, etc.
5. Peptic ulcer or obstruction or other diseases that affect the absorption of oral medication.
6. Any neurological disorder that may cause cognitive impairment beyond the impact of AD.
7. Any psychiatric diagnosis or neuropsychiatric symptom (such as hallucinations, major depression, or delusions) that may interfere with the participant's study procedure.
8. A history of transient ischemic attack (TIA), stroke, or seizure in the 12 months prior to signing ICF.
9. The Hachinski Ischemic Index Scale (HIS) at screening \> 4 points.
10. ECG at screening or at baseline showing prolonged QTcF \[Fridericia correction formula, see Section 17.4\] (QTcF \> 480 ms in women; QTcF \> 470 ms in men) or other clinically significant abnormalities of the ECG that are considered by the investigator to be unsuitable for participation in a clinical study (e.g., heart rate \< 50 beats/min, sinus node lesions, Morse II or third-degree atrioventricular block, etc.).
11. The Geriatric Depression Scale (GDS) score at screening ≥ 8 points.
12. Contraindications to MRI scans, including pacemakers/defibrillators, ferromagnetic metal implants (in addition to those approved for safe use in MRI scanners, such as cranial and cardiac devices).
13. Contraindications with PET scanning, allergies to tracers.
14. Brain MRI at screening reveals evidence of other clinically significant lesions, suggesting a possible diagnosis of dementia other than AD.
15. Brain MRI at screening reveals the presence of a single hemorrhage with a maximum diameter \> 10 mm and investigator assesses the participant is unsuitable for this study; Evidence of angioedema.
16. Participants with inadequately controlled bleeding disorder (including platelet count \< 100,000/µL or international normalized ratio \[INR\] \> 1.5).
17. Thyroid stimulating hormone levels above or below the normal range. Participants with results of other thyroid function tests that fall outside the normal range will be excluded only if they are considered clinically significant by the investigator.
18. Laboratory test results for serum vitamin B12 levels below the normal range, as well as participants who are receiving vitamin B12 supplement therapy.
19. Positive serological finding for human immunodeficiency virus (HIV), active syphilis, Hepatitis B surface antigen (HBsAg), or Hepatitis C virus (HCV) antibody.
20. Any other clinically significant abnormalities in physical examination, vital signs, laboratory tests, or ECG present at screening or baseline that the investigator determines the situations that affected the safety of the participants or other interferences with the study.
21. Have a known or suspected history of drug or alcohol abuse.
22. Serious or unstable disease, or any other medical condition (e.g., heart, respiratory, gastrointestinal, liver, kidney, endocrine and nervous system disease, including poorly controlled hypertension, with a systolic blood pressure of ≥160mmHg or a diastolic blood pressure of ≥100 mmHg; Poorly controlled diabetes, etc.) that the investigator believes may affect the participant's safety or interfere with study evaluation.
23. Previous use of prohibited drugs, including disease-modifying drugs (Such as approved lecanemab, donemab, etc. or other disease-modifying investigational medicinal products), anti-oxidative stress drugs (other formulations of edaravone).
24. Have scheduled surgical procedures requiring general anesthesia during the study period. For a scheduled procedure that requires only local anesthesia and performed as a day procedure without the need for post-operative hospitalization, participant does not need to be excluded if the investigator determines that the procedure does not interfere with study procedures or participant safety.
25. Severe vision, hearing, reading, comprehension, or physical dysfunction that prevents the participant from accurately performing neuropsychological tests.
26. Have been diagnosed with serious active liver disease, such as acute hepatitis, chronic active hepatitis, cirrhosis, etc., or alanine transaminase (ALT) \> 2 × upper limit of normal (ULN) or aspartate aminotransferase (AST) \> 2 × ULN, or total bilirubin (TBIL) \> 1.5 × ULN.
27. Have been diagnosed with severe active kidney disease, renal insufficiency; or serum creatinine \> 1.5 × ULN or creatinine clearance \< 50 mL/min at screening and baseline (Calculated based on the Cockcroft-Gault formula, see Section 17.6 for details).
28. Have severe systemic disease and life expectancy is \< 2 years.
29. Answer "yes" to C-SSRS suicidal ideation Type 4 or 5, or any suicidal behavior assessment within 6 months before screening, at screening, or at the baseline visit, or has been hospitalized or treated for suicidal behavior in the past 5 years before screening.
30. Allergic to edaravone, sodium bisulfite, or soluplus excipients (Note: Asthma patients are sensitive to sulfites and may have allergic reactions. For patients with a history of asthma, the investigator will carefully assess whether to enroll them.).
31. History of major surgery within 4 weeks prior to enrollment.
33. Participants who have received cholinesterase inhibitors, memantine within 12 weeks prior to randomization and stopped treatment due to safety concerns or other reasons and refuse to or unable to receive it again.
34. Female participants who are pregnant, breastfeeding, planning to become pregnant recently, or unwilling to use contraceptive measures.
35. Have other conditions that investigator believes the participant is unsuitable for this study.
Minimum Eligible Age
60 Years
Maximum Eligible Age
85 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Auzone Biological Technology Co., Ltd.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Daping Hospital.
Chongqing, Chongqing Municipality, China
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
China
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TTYP01-Ⅱ-AD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
NCT07066826
NOT_YET_RECRUITING
PHASE2/PHASE3
Safety and Efficacy of MT-4666
NCT01764243
COMPLETED
PHASE2
Efficacy and Safety of 1612 Capsules in aMnestic Mild Cognitive Impairment
NCT02982642
WITHDRAWN
PHASE4
Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease
NCT01282619
UNKNOWN
PHASE2/PHASE3
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease
NCT01966666
COMPLETED
PHASE1
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
NCT01689233
COMPLETED
PHASE3
Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects
NCT04251182
COMPLETED
PHASE2
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
NCT01266525
COMPLETED
PHASE2
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
NCT01466088
COMPLETED
PHASE2
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
NCT01689246
COMPLETED
PHASE3
Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease
NCT04566003
COMPLETED
PHASE1
A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease
NCT01404169
COMPLETED
PHASE3
Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease
NCT01254448
COMPLETED
PHASE1
Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)
NCT06285240
COMPLETED
PHASE1
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578
RECRUITING
PHASE3
Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms
NCT02626572
COMPLETED
PHASE2
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
NCT03131453
TERMINATED
PHASE2/PHASE3
A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease
NCT02820896
COMPLETED
PHASE1
Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia
NCT02078310
COMPLETED
PHASE1/PHASE2
Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
NCT02080364
TERMINATED
PHASE3
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150
RECRUITING
PHASE3
A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
NCT03114657
TERMINATED
PHASE3
Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia
NCT07251023
RECRUITING
PHASE3
TRx0014 in Patients With Mild or Moderate Alzheimer's Disease
NCT00515333
COMPLETED
PHASE2
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
NCT06079190
ACTIVE_NOT_RECRUITING
PHASE2